BR112023024207A2 - Composição para o tratamento de condições autoimunes, aloimunes, inflamatórias e mitocondriais e usos das mesmas - Google Patents

Composição para o tratamento de condições autoimunes, aloimunes, inflamatórias e mitocondriais e usos das mesmas

Info

Publication number
BR112023024207A2
BR112023024207A2 BR112023024207A BR112023024207A BR112023024207A2 BR 112023024207 A2 BR112023024207 A2 BR 112023024207A2 BR 112023024207 A BR112023024207 A BR 112023024207A BR 112023024207 A BR112023024207 A BR 112023024207A BR 112023024207 A2 BR112023024207 A2 BR 112023024207A2
Authority
BR
Brazil
Prior art keywords
alloimmune
inflammatory
autoimmune
treatment
composition
Prior art date
Application number
BR112023024207A
Other languages
English (en)
Inventor
Trevor Klee
Original Assignee
Trevor Klee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trevor Klee filed Critical Trevor Klee
Publication of BR112023024207A2 publication Critical patent/BR112023024207A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/14—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.14.14)
    • C12Y114/14001—Unspecific monooxygenase (1.14.14.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin

Abstract

usos de um inibidor de calcineurina e um inibidor de citocromo p450 no tratamento de condições autoimunes, aloimunes, inflamatórias e mitocondriais. a presente invenção refere-se a composições e métodos para o tratamento de condições autoimunes, aloimunes, inflamatórias e mitocondriais.
BR112023024207A 2021-05-21 2022-05-20 Composição para o tratamento de condições autoimunes, aloimunes, inflamatórias e mitocondriais e usos das mesmas BR112023024207A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163191835P 2021-05-21 2021-05-21
US202163240217P 2021-09-02 2021-09-02
PCT/US2022/030179 WO2022246146A2 (en) 2021-05-21 2022-05-20 Composition for treating autoimmune, alloimmune, inflammatory, and mitochondrial conditions, and uses thereof

Publications (1)

Publication Number Publication Date
BR112023024207A2 true BR112023024207A2 (pt) 2024-01-30

Family

ID=84141858

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023024207A BR112023024207A2 (pt) 2021-05-21 2022-05-20 Composição para o tratamento de condições autoimunes, aloimunes, inflamatórias e mitocondriais e usos das mesmas

Country Status (7)

Country Link
EP (1) EP4340822A2 (pt)
KR (1) KR20240012533A (pt)
AU (1) AU2022277913A1 (pt)
BR (1) BR112023024207A2 (pt)
CA (1) CA3218585A1 (pt)
IL (1) IL308668A (pt)
WO (1) WO2022246146A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024010885A1 (en) * 2022-07-08 2024-01-11 Klee Trevor Composition for intermittent dosing of calcineurin inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512549A (ja) * 2013-03-14 2016-04-28 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ

Also Published As

Publication number Publication date
IL308668A (en) 2024-01-01
CA3218585A1 (en) 2022-11-24
WO2022246146A2 (en) 2022-11-24
KR20240012533A (ko) 2024-01-29
WO2022246146A3 (en) 2022-12-29
AU2022277913A1 (en) 2023-11-16
EP4340822A2 (en) 2024-03-27

Similar Documents

Publication Publication Date Title
BR112018070852A2 (pt) composições de dissulfeto de selênio para uso no tratamento de disfunção das glândulas meibomianas
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
BR112022001415A2 (pt) Agentes interleucina-2 e os usos dos mesmos
BR112017007975A2 (pt) composições e métodos para o tratamento de disfunção das glândulas meibomianas
BR112022012594A2 (pt) Dosagem de gama-hidroxibutirato (ghb)
BR112017012946A2 (pt) ?composição hemostática, métodos para tratar uma lesão e para diminuir ou interromper sangramento, e, kit para o tratamento de uma lesão?
BR112023021068A2 (pt) Compostos, composições e métodos para tratar câncer
BR112023024207A2 (pt) Composição para o tratamento de condições autoimunes, aloimunes, inflamatórias e mitocondriais e usos das mesmas
BR112021025676A2 (pt) Composições e métodos para tratar uma afecção mediada por th2 com o uso de prevotella
CL2021002669A1 (es) (divisional de solicitud 3443-2018) tratamientos de cancer.
BR112016021011A8 (pt) composição tópica e usos de um composto
MX2022012536A (es) Composiciones que comprenden polisacaridos sulfatados.
BR112016018085A8 (pt) composições sinérgicas de suplemento dietético para prevenção, tratamento ou controle de doenças inflamatórias e respectivo método de aplicação das composições sinérgicas
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
CO2022000481A2 (es) Inhibidores de enzimas
BR112023001792A2 (pt) Combinações para o tratamento de câncer
BR112021023832A8 (pt) Métodos e composições para geração de óxido nítrico e usos dos mesmos
BR112022020441A2 (pt) Composições compreendendo nanopartículas, método de fabricação e usos das mesmas
MX2021009535A (es) Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación.
BR112021026258A2 (pt) Composições de melanoidina, usos das composições e método para tratar plantação
CL2022001779A1 (es) Composiciones que comprenden aminoácidos para la prevención y/o el tratamiento del cáncer
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
CO2021014747A2 (es) Métodos para el tratamiento de βeta-talasemia
BR112022024988A2 (pt) Compostos e métodos para tratamento de infecções fúngicas
BR112022011207A2 (pt) Composições para cuidados pessoais e métodos para estas